Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$265.0K+63.42%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ram Mukunda
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 70
- Beta
- 0.49
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -17.11
Financials
Revenue
$265.0K+63.4%Net Income
$-2.94MEBITDA
$-2.73MFree Cash Flow
$-1.35MEPS (diluted)
$-0.03Shares Outstanding (diluted)
100.33M+324.5%Operating Expenses
$2.83MCash & Debt
$354.0KReturn of Capital
$0.00Revenue by Segment (annual)
$1.16MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.19M | $-6.55M | $-0.07 |
| 2025 | $1.27M | $-7.12M | $-0.09 |
| 2024 | $1.34M | $-13.00M | $-0.22 |
| 2023 | $911.0K | $-11.51M | $-0.22 |
| 2022 | $397.0K | $-15.02M | $-0.30 |
| 2021 | $898.0K | $-8.81M | $-0.21 |
| 2020 | $4.07M | $-7.32M | $-0.19 |
| 2019 | $5.12M | $-4.10M | $-0.12 |
| 2018 | $2.19M | $-1.79M | $-0.06 |
| 2017 | $580.4K | $-1.87M | $-0.07 |
| 2016 | $6.37M | $-2.81M | $-0.17 |
| 2015 | $7.68M | $-4.61M | $-0.31 |
| 2014 | $2.27M | $-3.02M | $-0.37 |
| 2013 | $8.03M | $-2.25M | $-0.32 |
Valuation
IGChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+66.67%Social Signal Score
Mentions (3)
- Newsaccessnewswire.com·8d ago·Neutral
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 POTOMAC, MD / ACCESS Newswire / September 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead asset, IGC-AD1, for agitation in Alzheimer's dementia. Enrollment complete; final participant dosing expected to conclude in early November; topline results expected Q4 2026 CALMA achieved target e…
View source ↗ - Newsaccessnewswire.com·50d ago·Neutral
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer's disease, today announced financial results for the second quarter ended June 30, 2026, and pr…
View source ↗ - Newsaccessnewswire.com·56d ago·Negative
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that it is strengthening its regulatory, biostatistical, artificial intelligence ("AI")-enabled data science, and strategic pharmaceutical development ca
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.02 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.03 vs $-0.02miss
- Fri, May 15$-0.02 vs $-0.02beat
- Fri, Mar 20$-0.02 vs $-0.02beat
- Fri, Nov 14$-0.02 vs $-0.02beat
- Tue, Aug 19$-0.02 vs $-0.03beat
- Mon, Jun 30$-0.02 vs $-0.02beat
Estimates and results for IGC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IGC officers and directors.
- Bought
- $200k
- Sold
- —
1 trade
0 trades
- Moran James Pbought
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IGC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.